Lessons From COVID-19: How Pharma Supply Chains Must Evolve Before Next Disaster
Experts describe the agile, localized supply chains that will emerge, only perhaps to be forgotten just-in-time for the next crisis.
You may also be interested in...
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Gilead, Vetter, Lonza and academic experts share what they’re focusing on to keep producing drugs during the pandemic.
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.